Tenon Medical, Inc. (TNON) Stock Price & Analysis
Tenon Medical, Inc. (TNON) rose 2.77% to USD 0.62 as of June 10, 2026 at 02:01 UTC, according to Nexqual real-time market data.
TNON last closed at USD 0.6; the session ranged USD 0.59–0.63 on volume of 262,480 shares. Market capitalization is $7.14M, with a 52-week range of USD 0.58–2.48 (NCM). Source: Nexqual, June 10, 2026 at 02:01 UTC.
Key Statistics (as of June 10, 2026 at 02:01 UTC)
| Price | USD 0.62 |
|---|---|
| Change | ▲ 2.77% (up) |
| Previous Close | USD 0.6 |
| Open | USD 0.63 |
| Day Range | USD 0.59 – 0.63 |
| 52-Week Range | USD 0.58 – 2.48 |
| Volume | 262,480 shares |
| Market Cap | $7.14M |
| Exchange | NCM |
Technical Analysis (TNON)
Nexqual's technical model rates TNON "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:01 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 30.88 (neutral) |
| vs SMA50 | Below (USD 0.73) |
| MACD | -0.04 (negative) |
Analyst Ratings (TNON)
Wall Street analysts rate TNON "None" based on 2 analysts, with a mean price target of USD 2.63 (range USD 2.25–3), per Nexqual as of June 10, 2026 at 02:01 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 2.63 |
| High Target | USD 3 |
| Low Target | USD 2.25 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (TNON)
| Next Earnings Date | 2026-05-12 |
|---|---|
| EPS Estimate | USD -0.24 |
| Revenue Estimate | $1.54M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.22 vs est -0.36 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -0.37 ▼ miss |
| 2025-06-30 | USD -0.36 vs est -0.47 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:01 UTC.
Financials & Fundamentals (TNON)
| Total Revenue | $4.60M |
|---|---|
| Revenue Growth (YoY) | +89.90% |
| Gross Margin | +64.83% |
| Operating Margin | -237.85% |
| Profit Margin | -270.09% |
| ROE | -220.32% |
| Debt / Equity | 257.36 |
| Current Ratio | 1.03 |
| Total Cash | $4.61M |
| Total Debt | $4.88M |
Source: Nexqual, June 10, 2026 at 02:01 UTC.
Financial Health Score (TNON)
Nexqual rates Tenon Medical, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:01 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $5M cash vs $5M debt |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -220%, ROA -55.4% |
Ownership (TNON)
| Insider Ownership | +13.77% |
|---|---|
| Institutional Ownership | +3.17% |
| Shares Outstanding | 11.57M |
| Float | 10.15M |
| Short % of Float | +1.41% |
Source: Nexqual, June 10, 2026 at 02:01 UTC.
Leadership (TNON)
Tenon Medical, Inc. is led by Steven M. Foster (age 57), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:01 UTC.
| CEO, President & Director | Steven M. Foster (age 57) |
|---|---|
| Founder & Executive Chairman | Richard M. Ferrari (age 71) |
| Founder, CTO, COO & Director | Richard Ginn (age 59) |
| CFO & Secretary | Kevin Williamson (age 39) |
Major Backers & Investors (TNON)
Notable institutional backers of Tenon Medical, Inc. include Fidelity, SBI Securities Co., Ltd., according to Nexqual as of June 10, 2026 at 02:01 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.29% |
| SBI Securities Co., Ltd. | 0.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.63% |
| Geode Capital | 1.45% |
| Northern Trust | 0.16% |
Source: Nexqual, June 10, 2026 at 02:01 UTC.
From Tenon Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed The Catamaran ® ™ SI Joint Fusion System ("The Catamaran System") that offers a novel, less invasive approach to the SI Joint using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain.
- Food and Drug Administration ("FDA") clearance in 2018 for The Catamaran System and are currently focused on the US market.
- The Catamaran System is a singular implant designed with several proprietary components which allow for it to be explicitly formatted to address the SI Joint with a single, less invasive approach and implant.
- We believe The Catamaran System will address a large market opportunity with a superior product and is distinct from other competitive offerings in the following ways:                     The Catamaran System is a singular implant designed with several proprietary components which allow for it to be explicitly formatted to transfix the SI Joint with a single approach and implant.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SKYA | SkyAI, Inc. | USD 1.16 | ▼ 4.13% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
| XPON | Expion360 Inc. | USD 0.45 | ▼ 6.03% |
| INBS | Intelligent Bio Solutions Inc. | USD 2.42 | ▼ 1.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:01 UTC. This page is informational and not investment advice.